Computing the Cost of Care per Patient per Day for Patients With Metastatic Neuroendocrine Neoplasms.

Autor:	Gupta DM; Northwestern University, Feinberg School of Medicine, Chicago, IL., Barnes J; University of Washington School of Medicine, Seattle,WA., Qin F; Stanford University School of Medicine, Stanford, CA., Kapphahn K; Stanford University School of Medicine, Stanford, CA., Hornbacker K; Stanford University School of Medicine, Stanford, CA., Blayney DW; Stanford University School of Medicine, Stanford, CA., Kunz PL; Yale School of Medicine, New Haven, CT.
Jazyk:	angličtina
Zdroj:	JCO oncology practice [JCO Oncol Pract] 2024 Feb; Vol. 20 (2), pp. 203-211. Date of Electronic Publication: 2023 Dec 14.
DOI:	10.1200/OP.23.00433
Abstrakt:	Purpose: Patients with well-differentiated, low-grade metastatic neuroendocrine neoplasms (NENs) usually have a long median survival and require complex, expensive care over many years at multidisciplinary centers. The cost burden for patients and institutions serves as a barrier to care. Understanding the drivers of these costs and whether intense monitoring adds value will help to optimize value-based care. Methods: We adapted the cost of care per patient per day (CCPD) validated methodology to measure cost while accounting for varying follow-up duration. We queried the Stanford NEN Database, which aggregates data from the electronic health record and other electronic sources, to study patients with metastatic NENs receiving regular care at Stanford. Current Procedural Terminology codes for services incurred during the monitoring period for each patient were mapped to the corresponding cost conversion factor and date in the Medicare fee schedule. Results: Two hundred two patients between 2010 and 2017 were studied with a mean CCPD of $119.11 in US dollars (USD); NEN-specific systemic therapy made up 55% of this cost. Somatostatin analogs were the costliest systemic therapy. Systemic therapy was the driver of cost differences among patients with various primary tumor types, stage of disease, tumor differentiation and grade, and functional hormone status. Patients in the most expensive CCPD group did not have a significant survival benefit ( P = .66). Conclusion: The CCPD methodology was effective in studying cancer care value in NENs. Systemic therapy, specifically somatostatin analogs, was the primary driver of cost, and intense monitoring and higher-cost care did not improve survival outcomes.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu